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In this era of growing molecular sophistication and
interest in genome-wide analyses to develop prognostic
signatures, it is ironic that some of the most promising
recent developments in predictive markers for colorectal
cancer stem from the re-emergence of interest in two well-
established and characterized molecular alterations. In this
issue of Annals of Surgical Oncology, Nash et al. present
two very interesting studies; the ﬁrst examines the associ-
ation of microsatellite instability (MSI) and K-ras mutation
status with prognosis in patients with colorectal cancer,
1
while the second evaluates the impact of K-ras (and Ki-67)
on the rate and extent of progression of hepatic metastases
from colorectal cancer.
2 Although done in retrospective
fashion, both studies report on a substantial number of
patients (n = 532 and 188, respectively) and the authors
add further credence to previously reported associations for
these particular genetic alterations.
MSI, found in approximately 20% of patients with
colorectal cancer, has been linked with favorable outcome
in young patients.
3 Using a modiﬁed three-locus assay for
MSI (BAT25, BAT26, and D2S123), Nash et al. conﬁrm
this association, and demonstrate a signiﬁcant survival
advantage (5-year survival 92% versus 59%, P\0.001),
which is more apparent in stage II patients. As described
previously, patients with MSI tend to have more poorly
differentiated, mucin-producing tumors, which are more
often found proximal to the splenic ﬂexure, characteristics
which were echoed in this study. This survival beneﬁt was
borne out in a multivariate hazards model even after
adjusting for stage. Although the retrospective nature of this
study and the heterogeneity of therapy may lead to bias, this
result is not surprising, given the strong association of MSI
with patient outcome. Of substantial current interest is that,
in addition to being a prognostic marker, several high-
proﬁle studies have described MSI as a predictive marker of
treatment that may predict variable response to 5-ﬂouro-
uracil (5-FU)-based chemotherapy.
4–6 This association is
being further explored as a part of the Eastern Cooperative
Oncology Group (ECOG) 5202 trial that is selecting stage II
colorectal cancer patients for adjuvant therapy based on
MSI and 18q loss-of-heterozygosity (LOH) status. The
current study by Nash et al. is not able to address this
speciﬁc issue; however, they do contribute to a strong
argument that MSI may be critical for both patient prog-
nosis and prediction of treatment outcome.
Similarly, K-ras has received substantial recent attention
given multiple reports of mutated K-ras being critical as a
predictive factor for lack of response to epidermal growth
factor receptor inhibitors such as cetuximab and pani-
tumumab in patients with colorectal cancer.
7–10 Moreover,
K-ras mutations on codon 12 have been associated with
unfavorable outcomes, especially in those individuals with
advanced disease. K-ras remains one of the commonly
mutated oncogenes in human cancers, and the association of
K-ras with colorectal cancer prognosis, independent of
stage, is controversial.
11,12 Nash et al. demonstrate in their
study that K-ras is independently associated with worse
outcome (5-year survival 55% versus 68%), with effects
being more pronounced in stage II and III disease. An
interesting and novel aspect of the papers, although slightly
weakened by the lack of an a priori hypothesis, is the
combined analysis of MSI and K-ras in determining the
prognosis of colorectal cancer patients, which has not been
previously described. In addition, the authors demonstrate
an association of K-ras mutation with worse outcomes and
accelerated progression of colorectal liver metastasis in
patients having undergone surgical resection. The retro-
spective nature of these analyses is also associated with
signiﬁcant heterogeneity of treatment, which may lend bias
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DOI 10.1245/s10434-009-0712-1to their conclusions. Nonetheless, the authors should be
commended for their meticulous analysis of a large number
of patients and samples and their results are certainly quite
compelling. Once again, it is very interesting that both
K-ras and MSI may serve roles in predicting survival as
well as in treatment selection.
In this era of targeted therapies and personalized med-
icine, it is clear that molecular markers will play a
substantial role in determining both patient treatment and
outcomes. However, the ﬁeld of molecular prognostication
can be fraught with the risk of inaccuracy, and promising
results must be rigorously validated in prospective studies
before incorporating the use of such markers into standard
practice.
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